Customize
Quick Links

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 30.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 30.0 Contact Hours.

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit http://www.absurgery.org

Main Symposium: Designated for a maximum of 25.5 AMA PRA Category 1 Credits™ (25.5 Contact Hours)
Mini Symposium: Designated for a maximum of 4.5 AMA PRA Category 1 Credits™ (4.5 Contact Hours)

Accreditation/Credit Designation (Mini Symposium)

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 4.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Acelity, Celgene Corporation, Daiichi Sankyo, Inc., Eisai, Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer Inc., and Puma Biotechnology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

35th Annual Miami Breast Cancer Conference®

35th Annual Miami Breast Cancer Conference®


March 8-11, 2018
Fontainebleau Miami Beach
4441 Collins Avenue
Miami Beach, FL 33140

Overview

The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer Conference® has been bringing together surgical, medical, and radiation oncologists, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. At Miami Breast Cancer Conference®, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from Acelity, AstraZeneca, Celgene Corporation, Daiichi Sankyo, Inc., Genomic Health, Inc., Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer Inc., and Puma Biotechnology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
 

Learning Objectives

  • Implement the new staging system for breast cancer by incorporating patient biomarkers and multifactorial prognostic panel information to appropriately stage and inform clinical decision-making
  • Summarize clinical trial evidence that allows for the personalization of care in the management of early and advanced forms of breast cancer
  • Select multimodal evidence-based treatment approaches to optimize outcomes for patients with non-metastatic breast cancer
  • Outline multidisciplinary methods to identify and manage treatment-related toxicities for patients with breast cancer
  • Appraise the influence on evolving treatment paradigms of recent clinical trial data pertaining to novel breast cancer treatment strategies

Mini-Symposium

The Miami Breast Cancer Conference® Mini-Symposium offers an additional educational opportunity for attendees who plan to arrive in Miami the day before the official conference begins. The Mini-Symposium takes the format of a World-Class Tumor Board, featuring cases and discussions that highlight challenging clinical situations commonly faced by surgeons and oncologists. This special session was developed to be of interest to healthcare practitioners from all specialties, and will provide practical information to enhance patient care in the clinic, delivered by top experts in the field of breast cancer. If your schedule allows, we hope you will plan to attend and take advantage of this extra session!

Note: Separate registration is required.

Program Chair

Patrick I. Borgen, MD
Chair, Department of Surgery
Maimonides Medical Center
Director, Brooklyn Breast Cancer Program
Brooklyn, NY
 
 

Program Co-Chairs

Kimberly L. Blackwell, MD
Professor of Medicine
Assistant Professor of Radiation Oncology
Duke University Medical Center
Durham, NC
 

Elizabeth Mittendorf, MD, PhD
Robert and Karen Hale Distinguished Chair in Surgical Oncology
Director, Breast Immuno-Oncology Program
Dana-Farber/Brigham and Women's Cancer Center
Boston, MA
 

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Curriculum Committee

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Translational Investigation
University of Pittsburgh
Pittsburgh, PA


Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCS(C)
Associate Professor of Surgery (Oncology)
Assistant Director, Global Oncology
Yale Comprehensive Cancer Center
New Haven, CT


William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Deputy Director, Clinical Network
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women's Cancer Care
Interim Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL


Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient
Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA


Patrick W. Whitworth, MD
Director
Nashville Breast Center
Nashville, TN








Become a Member

Forgot Password?
Filter By